<DOC>
	<DOCNO>NCT00766467</DOCNO>
	<brief_summary>The purpose research study determine armodafinil safe effective treat fatigue patient malignant gliomas undergoing treatment radiotherapy plus temodar . Armodafinil wakefulness-promoting agent FDA approve treatment excessive daytime sleepiness variety disorder . Armodafinil may also help reduce radiation-induced fatigue brain tumor patient .</brief_summary>
	<brief_title>A Randomized Placebo-Controlled Trial Armodafinil ( Nuvigil ) Fatigue Patients With Malignant Gliomas</brief_title>
	<detailed_description>- Since one know certain armodafinil improves fatigue brain tumor patient undergo radiation therapy , participant randomize one two study group . Half participant receive armodafinil half receive pill medicine ( placebo ) . Neither participant study doctor know group . - Participants give study medication-dosing calendar take either study drug placebo orally day 8 week . The dose adjusted day 8,22 43 , depend upon level fatigue . Treatment begin within 10 day radiation start date . - Participants evaluate via documented clinician telephone call self-administered questionnaire day 1 , 8 , 22 , 43 57 .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>18 year age old Histologically confirm malignant glioma include anaplastic astrocytoma , anaplastic oligodendroglioma , anaplastic oligoastrocytoma ( WHO grade III/IV ) , glioblastoma multiforme ( WHO grade IV ) gliosarcoma . Patients grade II astrocytoma , mixed oligoastrocytoma oligodendroglioma treat irradiation also eligible Scheduled receive irradiation total dose 5060 Gy . Patients receive hyperfractionated radiotherapy also eligible KPS 70 % great Electrolytes within normal institutional limit : BUN Creatinine &lt; 2.5 x ULN : AST , ALT , Bilirubin &lt; 2.5 x ULN Able swallow medication History recent cardiac arrhythmia unstable angina Has take psychostimulant monoamine oxidase inhibitor regular basis within past 30 day Clinically significant untreated sleep apnea A history clinically significant cardiac disease , include history recent myocardial infarction , history unstable angina , history leave ventricular hypertrophy , history ischemic ECG change , chest pain , arrhythmia , clinically significant manifestation mitral valve prolapse association use CNS stimulant ( e.g . caffeine , amphetamine , methylphenidate ) Uncontrolled hypertension , alcohol drug abuse , severe headache , glaucoma , narcolepsy , clinically significant untreated sleep apnea , psychotic disorder Tourette 's syndrome Patients take warfarin anticoagulation eligible , monitor prothrombin time suggest precaution Hemoglobin level le 11 g/dl Laboratory evidence hypothyroidism elevate TSH concentration blood great 5.0 mlU/L Current treatment history psychotic disorder , bipolar disorder , anxiety disorder Patients score &gt; 28 Beck depression inventory consistent severe depression Known hypersensitivity armodafinil related compound Patients receive MAO inhibitor past 14 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>armodafinil</keyword>
	<keyword>Nuvigil</keyword>
	<keyword>fatigue</keyword>
</DOC>